Novo Nordisk’s strategy, announced at its 21 September 2026 Capital Markets Day, is to advance more drug programmes, expand oral GLP-1 capacity and reach more patients. The company set targets for 2030 and 2035, but they are ambitions—not achieved results or independent forecasts. Its plan builds on marketed Wegovy products while relying on investigational candidates whose development and availability remain uncertain.
What Novo Nordisk announced
At its London Capital Markets Day on 21 September 2026, Novo Nordisk said it was updating its corporate strategy and strategic ambitions. The targets combine prospective product launches, pipeline activity and patient reach:
| Company ambition | Target date | What it means |
|---|---|---|
| Launch more than five “multi-blockbusters” | By 2030 | The company’s own label for an intended group of major products; it is an ambition, not an objective measure of commercial success. |
| Serve more than 60 million patients globally | By 2030 | A patient-reach target; it is not a reported current patient count. |
| Build capacity to serve ten times more people with obesity on oral GLP-1 medicines | By 2030 | A scale-up goal for oral treatment capacity, not a claim that ten times as many people are already being treated. |
| Have at least five Phase 3 programmes in obesity and diabetes, and at least five in other therapy areas | Strategic ambition | The company aims to expand late-stage development across these areas; the announcement does not make these programmes approved products. |
| Generate more than DKK 150 billion in pipeline sales | In 2035 | A future sales ambition tied to pipeline products, not current revenue or an independently validated forecast. |
These figures are goals set by Novo Nordisk. They do not establish how likely the company is to meet them. Novo Nordisk’s Capital Markets Day announcement describes the update as a presentation of its corporate strategy and 2030 ambitions.
How the plan builds on Wegovy and the existing portfolio
Novo Nordisk’s Q2 2026 investor presentation lists Saxenda, Wegovy 2.4 mg, Wegovy HD (semaglutide 7.2 mg) and Wegovy pill (semaglutide 25 mg) as marketed in the presentation’s context. It specifically identifies the pill as marketed in the United States. These labels describe the company’s portfolio snapshot, not universal availability: regulatory status, launch timing and supply can differ by country.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstall#1 Best Overall
The company also reported dated launches in selected markets. It said the Wegovy pill launched in the UAE in June 2026 and the UK in July 2026. It reported Wegovy HD launched in the United States in April, and a 7.2 mg single-dose pen in the UK in June. Its Q2 filing said rollout in the EU was planned for the second half of 2026; a planned launch is not confirmation that a medicine is available to an individual patient. Novo Nordisk’s Q2 2026 filing provides the company’s dated rollout snapshot.
Which obesity candidates are in development?
The portfolio strategy depends on products at different stages, not just the formulations already marketed. The statuses below reflect Novo Nordisk’s Q2 2026 investor presentation and should not be generalized across countries or treated as approvals.
Rank #2
- Amazon One Medical On-Demand Care telehealth telemedicine video direct message virtual treatment cash pay as you go no insurance. Previously Pay-per-visit (PPV)| Treated by online doctor dr MD nurse practitioner NP physician's assistant PA. FSA/HSA eligible reimburse| Treatment for adult human men women man woman para hombre mujer| Get virtual care, health service, diagnosis, remedy, remedies, cure, side effect management| Treated with fda approved medication, appetite suppressant, not supplement or detox product supplies| Prescriptions generic compounded like GLP1 agonist semaglutide tirzepatide orforglipron| Brand RX like Zepbound Wegovy Saxenda Foundayo| 30 28 day supply weekly daily dosing titration| Strengths like 5 mg 2.5 mg 10 mg 15 mg 12.5 mg 0.25 mg 0.5 mg 1 mg 1.7 mg 2.4 mg 7.5 mg 15 mg 0.6 mg 1.2 mg 1.8 mg 3 mg 1.5 mg 4 mg 9 mg 25 mg 0.8 mg 5.5 mg 14.5 mg 17.2 mg| Medicine forms like injection shot pills tablets refills tab capsule liquid pastilla tableta compounded pen injectable syringe Kwikpen
| Product or candidate | Status in the Q2 2026 presentation | What the status tells a reader |
|---|---|---|
| CagriSema | Submitted in the United States | A regulatory submission is not the same as approval or availability. |
| Cagrilintide | Phase 3 | Late-stage clinical development; not an established treatment on the basis of this status. |
| Subcutaneous zenagamtide | Phase 3 | Late-stage development of an injectable candidate. |
| Oral zenagamtide | Phase 3 initiation planned | A planned programme start, not a completed trial or a marketed oral medicine. |
| Efruxifermin | Phase 3 | A late-stage programme listed in the company presentation. |
| UBT251 | Phase 2 | Earlier development than Phase 3; further testing would be needed. |
The presentation also lists other early-stage candidates. A development-stage label describes where a programme stood in that company snapshot; it does not predict whether a candidate will succeed, be approved, or reach a particular market. Novo Nordisk’s Q2 2026 investor presentation is the source for these portfolio statuses.
Why CagriSema and zenagamtide matter to the approach
Novo Nordisk’s 2025 annual report describes an R&D approach that builds on incretin biology and advances dual and triple agonists, with the aim of addressing weight, blood glucose, cardiovascular risk and related conditions. It describes CagriSema as a once-weekly combination of cagrilintide and semaglutide, and zenagamtide as an agonist of GLP-1 and amylin receptors. These mechanisms illustrate the company’s research direction; they do not establish that either candidate is an approved or available treatment. Novo Nordisk’s 2025 annual report gives the company’s descriptions.
What clinical weight-loss figures do—and do not—show
Novo Nordisk’s 2025 annual report reports results from trials, but the percentages require their study context. In REDEFINE 1, CagriSema produced 22.7% weight loss versus 2.3% with placebo at 68 weeks under the estimate assuming all participants adhered to treatment; more than 40% of participants reached at least 25% weight loss. These are trial findings under a specified estimate, not a promise of typical results in routine care.
The same annual report gives an all-participants-adhered-to-treatment estimate of 16.6% weight loss for oral semaglutide 25 mg. The report described the pill as approved for chronic weight management at the time of publication. That historical description should not be read as a current approval or availability statement for every country; regulatory and market status vary.
Rank #4
Those figures are not a like-for-like head-to-head comparison between the pill and CagriSema. The reported measures come from distinct evidence contexts, and the materials cited here do not establish a comparative product ranking. For treatment decisions, a clinician can interpret the relevant local label and evidence for an individual patient.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the strategy means for patients and investors
For patients, the headline is a company effort to broaden treatment formats and increase potential supply, especially for oral GLP-1 medicines. The strategy does not guarantee that a specific candidate will become a medicine, that a product will launch in a particular country, or that an eligible patient will be able to obtain it. Ask a local healthcare professional or regulator for current product status and prescribing information.
For investors, the ambitions set direction but are not proof of future sales, pipeline productivity or competitive advantage. Novo Nordisk’s Q2 2026 report recorded net sales of DKK 78,488 million, up 3% at constant exchange rates, and adjusted operating profit up 11% at constant exchange rates; it also recorded a DKK 6.3 billion non-cash impairment charge for pipeline assets, including DKK 4.0 billion for monlunabant. These are company-reported financial figures with accounting definitions and a comparison period; they should be read in the context of the filing, not treated as validation of the new targets. The Q2 2026 filing provides the company’s financial disclosures.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
